Dr Mariana Argenziano
Mariana holds a PhD in molecular biology from the University of SanMartin (Buenos Aires) and has worked at several universities in the US for more than eight years, specializing in stem cell biology. Throughout her experience in academic research, she gained distinct knowledge and expertise in both disease modelling and biobank building and in the differentiation of iPSCs into cardiac and neuronal cell types.
In 2022, Mariana joined the manufacturing team at Ncardia, where she pursues new iPSC manufacturing procedures and scale-up processes to support their application in regenerative medicine and drug discovery.
ArticleAn ethical shift in NHP research: iPSC-derived cardiomyocytes for safer pharmacology
As regulators move to phase out primate testing, NHP-derived iPSC cardiomyocytes are emerging as a scalable, ethical and scientifically robust alternative - offering drug developers a clear path to faster, more predictive, and more responsible innovation.
ArticleTime for change: non-human primates in drug research
As ethical pressures and new regulations shake up preclinical research, the industry faces a turning point: can we finally move beyond non-human primates? Dr Mariana Argenziano, Associate Director Manufacturing Technologies at Ncardia, discusses the innovations reshaping drug development and what’s coming next.